Sitemap
Update: July 26th, 2009
Sitemap of posts on Orshe.com
Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
Posts
- Category: Wall Street Journal (continued)
- A.M. Vitals: Johnson and Johnson Revamps McNeil
- A.M. Vitals: Judge Blocks Federal Funding of Embryonic Stem Cell Research
- A.M. Vitals: Judge Rules Pfizer’s 2019 Viagra Patent is Valid
- A.M. Vitals: Judge Seems Skeptical of Health Law’s Individual Mandate
- A.M. Vitals: Judge Won’t Nix Generic Version of Sanofi’s Lovenox
- A.M. Vitals: Justice Department Wants in on Whistleblower Suit Against Pfizer’s Wyeth
- A.M. Vitals: Kellogg Dinged for Claiming Rice Krispies Boost Immunity
- A.M. Vitals: Kids Being Prescribed Drugs Once Limited to Adults
- A.M. Vitals: Kids Falling Through the Cholesterol-Screen Cracks
- A.M. Vitals: Kindred to Buy RehabCare For About $900 Million
- A.M. Vitals: Latest J&J Recall Involves Two DePuy Hip Implants
- A.M. Vitals: Lilly Focuses on Alzheimer’s, Diabetes, Cancer
- A.M. Vitals: Lilly Profit Beats Analysts’ Expectations (By a Penny)
- A.M. Vitals: Lilly, Amylin Scrap Diabetes-Drug Partnership
- A.M. Vitals: Lilly’s 3Q Earnings Beat Expectations
- A.M. Vitals: Listeria Outbreak Deaths Total 23, CDC Says
- A.M. Vitals: Listeria-Contaminated Cantaloupes Tied to 13 Deaths
- A.M. Vitals: Liver Warning For Glaxo’s Alli and Xenical Weight-Loss Drugs
- A.M. Vitals: Looking to Progeria for Clues to Heart Disease
- A.M. Vitals: Loss of COBRA Extension Could Hurt 144,000 Monthly
- A.M. Vitals: Lung Cancer, Drink Ban, Insurance
- A.M. Vitals: Maine, Other States Want to Change Medicaid Programs
- A.M. Vitals: Malaria Studies in Mice Raise Hopes of New Treatment
- A.M. Vitals: Many Health Plans Might Lose ‘Grandfathered’ Status
- A.M. Vitals: McDonald’s Says it Needs Health Insurance Waiver
- A.M. Vitals: Mead Johnson Says Tests Find No Bacteria in Formula
- A.M. Vitals: Medco Expands European Presence; Pfizer Pulls Mylotarg
- A.M. Vitals: Medicaid Funding For States Clears the House
- A.M. Vitals: Medicare Committee Pits Specialty Against Specialty
- A.M. Vitals: Medicare Head Berwick Goes to the Hill
- A.M. Vitals: Medicare in the Budget-Cutting Crosshairs
- A.M. Vitals: Medicare Overhaul Unlikely to Be Part of Budget Talks
- A.M. Vitals: Medicare Will Pay for Dendreon’s Provenge
- A.M. Vitals: Medtronic Details $15.7 Million Paid to Doctors
- A.M. Vitals: Medtronic Will Fund Yale Study of Infuse Spinal Product
- A.M. Vitals: Medtronic’s New Heart Device; Medicare ‘Doc Fix’
- A.M. Vitals: Mela Sciences’ Melanoma Diagnostic On Track For Approval
- A.M. Vitals: Melanoma Set to Be a Hot Topic at ASCO
- A.M. Vitals: Merck and Roche in Hepatitis C Drug Marketing Pact
- A.M. Vitals: Merck CEO Defends R&D Investment
- A.M. Vitals: Merck Gets a Subpoena Over Drug Marketing
- A.M. Vitals: Merck Profit Falls 52% On Merger, Restructuring Costs
- A.M. Vitals: Merck Taps Frazier as CEO
- A.M. Vitals: Merck Third-Quarter Earnings Fall By Less Than Expected
- A.M. Vitals: Merck Will Apply for Suvorexant Approval This Year
- A.M. Vitals: Merck’s 2nd-Quarter Profit Rises; Announces More Layoffs
- A.M. Vitals: Merck’s First-Quarter Profit Beats Expectations
- A.M. Vitals: Microbicide Gel Trial in Africa Canceled
- A.M. Vitals: More Aggressive Cholesterol Screening for Kids to Be Advised
- A.M. Vitals: More Americans Uninsured
- A.M. Vitals: More Disclosure from J&J
- A.M. Vitals: More J&J Products Scrutinized By Congress
- A.M. Vitals: More Light Shed on J&J, FDA Communication
- A.M. Vitals: Most HIV Patients Lack Medications, Care
- A.M. Vitals: Mylan Being Probed By SEC Over Meeting
- A.M. Vitals: News from AHA
- A.M. Vitals: NIH to Freeze Grants for Embryonic Stem Cell Research
- A.M. Vitals: Novartis Aims to Accelerate Vaccine Production
- A.M. Vitals: Novartis Chairman Vasella Adds Same Title at Alcon
- A.M. Vitals: Novartis Drug Safety Questions; ‘Doc Fix’ Coming?
- A.M. Vitals: Novartis Says Experimental Gout Drug is Effective
- A.M. Vitals: Novartis to Scrap Two Drugs, Take $590 Million Charge
- A.M. Vitals: Novartis Won’t Develop Tasigna for Rare Stomach Cancer
- A.M. Vitals: Now It’s Teva’s Turn to Defend Brand-Name Drug Patents
- A.M. Vitals: NYC Can’t Ban Soda Purchases Using Food Stamps
- A.M. Vitals: Obama Administration Will Promote One-Year-Old Health Bill
- A.M. Vitals: Obama Directs $50 Million to U.S. HIV Patients
- A.M. Vitals: Obama Focus Back on Health Care
- A.M. Vitals: Omnicare’s Candid Earnings Call
- A.M. Vitals: Orphan Drugs Are Making it to Market, Report Finds
- A.M. Vitals: Panel Wants Clearer Language on Some Birth-Control Pills
- A.M. Vitals: Payer Negotiation is Next Up for AstraZeneca
- A.M. Vitals: Pfizer and Merck Diverge in a Tough Pharma World
- A.M. Vitals: Pfizer and Novartis Drugs Get FDA Panel Recommendation
- A.M. Vitals: Pfizer and Teva Report 3rd-Quarter Earnings
2009 -